Evidence map›Paper›PMID 33321938›Full record

ReviewAntioxidants (Basel, Switzerland)2020

Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia.

Marta Seco-Cervera, Pilar González-Cabo, Federico V Pallardó, Carlos Romá-Mateo, José Luis García-Giménez

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. HSPBiomedicines · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Emerging Roles of the Metabolic Regulator G6PD in Human Cancers.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marta Seco-CerveraCentre for Biomedical Research on Rare Diseases (CIBERER), 46010 Valencia, Spain.ORCID 0000-0002-4278-2835
Pilar González-CaboCentre for Biomedical Research on Rare Diseases (CIBERER), 46010 Valencia, Spain.
Federico V PallardóCentre for Biomedical Research on Rare Diseases (CIBERER), 46010 Valencia, Spain.ORCID 0000-0003-3715-1980
Carlos Romá-MateoCentre for Biomedical Research on Rare Diseases (CIBERER), 46010 Valencia, Spain.ORCID 0000-0002-7981-7157
José Luis García-GiménezCentre for Biomedical Research on Rare Diseases (CIBERER), 46010 Valencia, Spain.ORCID 0000-0001-7547-7872
Universitat de València · ES

Funding

Centro de investigación Biomedica en red en enfermedades raras-ISCIII ACCI-2018-22Centro de investigación Biomedica en red en enfermedades raras-ISCIII ACCI-2019-22Federación Española de Ataxias de España (FEDAES) N/AGeneralitat Valenciana PROMETEO/2018/135Instituto de Salud Carlos III PI19/010846
6 · The paper itself

Abstract

The thioredoxin family consists of a small group of redox proteins present in all organisms and composed of thioredoxins (TRXs), glutaredoxins (GLRXs) and peroxiredoxins (PRDXs) which are found in the extracellular fluid, the cytoplasm, the mitochondria and in the nucleus with functions that include antioxidation, signaling and transcriptional control, among others. The importance of thioredoxin family proteins in neurodegenerative diseases is gaining relevance because some of these proteins have demonstrated an important role in the central nervous system by mediating neuroprotection against oxidative stress, contributing to mitochondrial function and regulating gene expression. Specifically, in the context of Friedreich's ataxia (FRDA), thioredoxin family proteins may have a special role in the regulation of Nrf2 expression and function, in Fe-S cluster metabolism, controlling the expression of genes located at the iron-response element (IRE) and probably regulating ferroptosis. Therefore, comprehension of the mechanisms that closely link thioredoxin family proteins with cellular processes affected in FRDA will serve as a cornerstone to design improved therapeutic strategies.

Indexed as

Friedreich’s ataxiaglutaredoxinsoxidative stressthioredoxins

Identifiers

PMID33321938
PMCPMC7763308
OpenAlexW3111729561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.